Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | PTPRA | P18433 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499090 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1FFAR1 | |
| Hydrochloric Acid SCHEMBL28672925 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1FFAR1 | |
| Hydrochloric Acid SCHEMBL4174816 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1FFAR1 | |
| Ethylene Glycol SCHEMBL11535314 | 0.94 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1FFAR1 | |
| Ethylene Glycol SCHEMBL11532139 | 0.94 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1FFAR1 | |
| Sulfuric Acid SCHEMBL933256 | 0.93 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1FFAR1 | |
| 1,4-Butanediol SCHEMBL11531292 | 0.91 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1FFAR1 | |
| SCHEMBL6687222 | 0.89 | SMN1; SMN2 (0.73) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1HRH1 | |
| SCHEMBL3673389 | 0.89 | SMN1; SMN2 (0.73) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1HRH1 | |
| SCHEMBL2302450 | 0.87 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2025-05-20 | — | — | US | claimed |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2022-06-23 | — | — | US | claimed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | claimed |
| CN-114369060-A | Novel indoleamine 2, 3-dioxygenase inhibitor and application thereof in preparing antitumor drugs | 杭州星鳌生物科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-106117076-B | A kind of novel toluylene derivative and preparation method thereof | 北京理工大学 | 2018-11-06 | — | — | CN | claimed |
| CN-106117076-A | A kind of novel toluylene derivant and preparation method thereof | 北京理工大学 | 2016-11-16 | — | — | CN | claimed |
| WO-2005123727-A1 | 3-ARYL-3-HYDROXY- AND 3-ARYL-3-OXOPROPIONIC ACID ESTERS AS FUNGICIDES | CROPSOLUTION, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2004089357-A2 | ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2004-10-21 | — | — | WO | claimed |
| EP-0715623-A1 | PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | claimed |
| EP-0159640-A1 | 4-Methoxy-2,2'-bipyridyl-6-aldoximes, process and intermediates for their preparation and their use as medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-30 | — | — | EP | claimed |
| US-4153795-A | Cobalt pyridyl catalysts for hydroformylation | DIRECTOR-GENERAL OF THE AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1979-05-08 | — | — | US | claimed |
| JP-53012870-A | — | — | None | — | — | JP | disclosed |
| JP-62070360-A | — | — | None | — | — | JP | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-0074229-A1 | Triazole gastric anti-secretory agents | PFIZER INC. (US) | 1983-03-16 | — | — | EP | disclosed |
| US-4305945-A | Isoureas and isothioureas | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-15 | — | — | US | disclosed |
| US-4153795-A | Cobalt pyridyl catalysts for hydroformylation | DIRECTOR-GENERAL OF THE AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1979-05-08 | — | — | US | disclosed |
| JP-S5312870-A | 3-PYRIDYL-PROPIONIC ACID ALKYLESTERS | AGENCY OF IND SCIENCE & TECHNOL | 1978-02-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | HSD11B1, HSD11B2, CYP11B1 | SMN1; SMN2 1950/4885CYP1A2 84/4885CYP2C19 98/4885 |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | HSD11B1, HSD11B2, HSD17B1 | SMN1; SMN2 2050/4885CYP1A2 91/4885CYP2C19 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.